Show simple item record

dc.contributor.authorBreneman, John C.
dc.contributor.authorMeza, Jane L.
dc.contributor.authorDonaldson, Sarah S.
dc.contributor.authorRaney, R. Beverly
dc.contributor.authorWolden, Suzanne
dc.contributor.authorMichalski, Jeff M.
dc.contributor.authorLaurie, Fran
dc.contributor.authorRodeberg, David A.
dc.contributor.authorMeyer, William
dc.contributor.authorWalterhouse, David
dc.contributor.authorHawkins, Douglas S
dc.date2022-08-11T08:10:45.000
dc.date.accessioned2022-08-23T17:18:48Z
dc.date.available2022-08-23T17:18:48Z
dc.date.issued2012-06-01
dc.date.submitted2014-01-25
dc.identifier.citationInt J Radiat Oncol Biol Phys. Jun 1, 2012; 83(2): 720–726. Published online Nov 19, 2011. doi: 10.1016/j.ijrobp.2011.06.2011 <a href="http://dx.doi.org/10.1016/j.ijrobp.2011.06.2011">Link to article on publisher's site</a>
dc.identifier.issn0360-3016 (Linking)
dc.identifier.doi10.1016/j.ijrobp.2011.06.2011
dc.identifier.pmid22104356
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47934
dc.description.abstractPURPOSE: To analyze the effect of reduced-dose radiotherapy on local control in children with low-risk rhabdomyosarcoma (RMS) treated in the Children's Oncology Group D9602 study. METHODS AND MATERIALS: Patients with low-risk RMS were nonrandomly assigned to receive radiotherapy doses dependent on the completeness of surgical resection of the primary tumor (clinical group) and the presence of involved regional lymph nodes. After resection, most patients with microscopic residual and uninvolved nodes received 36 Gy, those with involved nodes received 41.4 to 50.4 Gy, and those with orbital primary tumors received 45 Gy. All patients received vincristine and dactinomycin, with cyclophosphamide added for patient subsets with a higher risk of relapse in Intergroup Rhabdomyosarcoma Study Group III and IV studies. RESULTS: Three hundred forty-two patients were eligible for analysis; 172 received radiotherapy as part of their treatment. The cumulative incidence of local/regional failure was 15% in patients with microscopic involved margins when cyclophosphamide was not part of the treatment regimen and 0% when cyclophosphamide was included. The cumulative incidence of local/regional failure was 14% in patients with orbital tumors. Protocol-specified omission of radiotherapy in girls with Group IIA vaginal tumors (n = 5) resulted in three failures for this group. CONCLUSIONS: In comparison with Intergroup Rhabdomyosarcoma Study Group III and IV results, reduced-dose radiotherapy does not compromise local control for patients with microscopic tumor after surgical resection or with orbital primary tumors when cyclophosphamide is added to the treatment program. Girls with unresected nonbladder genitourinary tumors require radiotherapy for postsurgical residual tumor for optimal local control to be achieved.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=22104356&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.ijrobp.2011.06.2011
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAge Factors
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectCombined Modality Therapy
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHead and Neck Neoplasms
dc.subjectHumans
dc.subjectInfant
dc.subjectInfant, Newborn
dc.subjectLymph Node Excision
dc.subjectLymphatic Metastasis
dc.subjectMale
dc.subjectNeoplasm, Residual
dc.subjectOrbital Neoplasms
dc.subjectProstatic Neoplasms
dc.subjectQuality Control
dc.subjectRadiotherapy Dosage
dc.subjectRhabdomyosarcoma, Embryonal
dc.subjecttherapy
dc.subjectSecond-Look Surgery
dc.subjectTreatment Failure
dc.subjectTumor Burden
dc.subjectUrogenital Neoplasms
dc.subjectYoung Adult
dc.subjectNeoplasms
dc.subjectOncology
dc.titleLocal control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study
dc.typeJournal Article
dc.source.journaltitleInternational journal of radiation oncology, biology, physics
dc.source.volume83
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiationoncology_pubs/42
dc.identifier.contextkey5020139
html.description.abstract<p>PURPOSE: To analyze the effect of reduced-dose radiotherapy on local control in children with low-risk rhabdomyosarcoma (RMS) treated in the Children's Oncology Group D9602 study.</p> <p>METHODS AND MATERIALS: Patients with low-risk RMS were nonrandomly assigned to receive radiotherapy doses dependent on the completeness of surgical resection of the primary tumor (clinical group) and the presence of involved regional lymph nodes. After resection, most patients with microscopic residual and uninvolved nodes received 36 Gy, those with involved nodes received 41.4 to 50.4 Gy, and those with orbital primary tumors received 45 Gy. All patients received vincristine and dactinomycin, with cyclophosphamide added for patient subsets with a higher risk of relapse in Intergroup Rhabdomyosarcoma Study Group III and IV studies.</p> <p>RESULTS: Three hundred forty-two patients were eligible for analysis; 172 received radiotherapy as part of their treatment. The cumulative incidence of local/regional failure was 15% in patients with microscopic involved margins when cyclophosphamide was not part of the treatment regimen and 0% when cyclophosphamide was included. The cumulative incidence of local/regional failure was 14% in patients with orbital tumors. Protocol-specified omission of radiotherapy in girls with Group IIA vaginal tumors (n = 5) resulted in three failures for this group.</p> <p>CONCLUSIONS: In comparison with Intergroup Rhabdomyosarcoma Study Group III and IV results, reduced-dose radiotherapy does not compromise local control for patients with microscopic tumor after surgical resection or with orbital primary tumors when cyclophosphamide is added to the treatment program. Girls with unresected nonbladder genitourinary tumors require radiotherapy for postsurgical residual tumor for optimal local control to be achieved.</p>
dc.identifier.submissionpathradiationoncology_pubs/42
dc.contributor.departmentQuality Assurance Review Center
dc.contributor.departmentDepartment of Radiation Oncology
dc.source.pages720-6


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record